Aurora Cannabis : Download Investor Relations Presentation PDF (6.73MB)

INVESTOR PRESENTATION

SEPTEMBER 2022

Disclaimer

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information contained in this presentation constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend" or the negative of these terms and similar expressions. Forward- looking statements in this presentation include, but are not limited to, statements with respect to the Company's strategy for achieving cost savings and the timing and path towards positive Adjusted EBITDA, the development of the Company's breeding and genetics licensing programs and the associated impact on revenue, cultivation efficiencies and variety in product pipeline, opportunities in the medical market, including but not limited to growing market share and increased benefit plan coverage, the development of innovative products for the market, the use of proceeds from the Company's shelf prospectus, the Company's ability to drive sales growth in the Canadian and International markets, expected gross margins in the Canadian medical segment, competitive advantages, including those with respect to entry into international medical and recreational markets including, but not limited to, Germany and the United States when cannabis is federally permissible, the acquisition of Thrive and associated benefits, including, but not limited to, the acceleration of the Company's position in the Canadian recreational market, the majority investment in Bevo Farms, including Bevo's growth plan, the repurposing of the Aurora Sky facility, and the associated benefits of the investment to the Company's business and path to profitability, and future growth opportunities. Forward-looking statements are based on certain opinions, estimates and assumptions of Aurora's management in light of management's experience and perception of historical trends, current conditions and expected developments at the time the statements are made, including expected growth, results of operations, performance, industry trends and conditions, the current and future regulatory environment and growth opportunities. While Aurora considers these opinions, estimates and assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Recipients are cautioned not to place undue reliance on forward-looking statements contained herein. Forward-looking statements also necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; future legislative and regulatory developments, including changes in laws; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the early stage of the cannabis industry in Canada generally and the CBD market in the U.S.; realization of funded production estimates; changes in tax treatment; the ability of Aurora to implement its business strategies; competition; product demand; changes in prices of required commodities; currency and interest rate fluctuations; the effects of and responses to the COVID-19 pandemic; that the adult consumer market for cannabis in Canada and CBD in the U.S. and the global medical cannabis market, will prove smaller than estimated; whether the Company will be able to identify consumer trends and stock desirable products, identify partnering opportunities, right-size production facilities, and maintain SG&A costs; and other risks and uncertainties set out under the heading "Risk Factors" in Aurora's annual information form dated September 20, 2022 and filed with Canadian securities regulators available on Aurora's issuer profile on SEDAR at www.sedar.comand filed with and available on the SEC's website at www.sec.gov.

Recipients are cautioned that the foregoing risks are not exhaustive and other factors could also adversely affect Aurora and its business and operations. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this presentation are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. Aurora disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

No securities of Aurora any kind are being offered as part of this presentation. Before making an investment of any kind in securities of Aurora, potential investors are urged to read Aurora's public disclosure materials filed under Aurora's issuer profile on SEDAR at www.sedar.comand filed with and available on the SEC's website at www.sec.gov.

Diversified Business Model Focus on Defensive, Stable, High Margin Segments

Canadian	International	Adult	Science &	Bevo
Medical	Medical	Recreational	Innovation	Acquisition

#1 Canadian Medical share by revenue

High margin, direct to consumer model

#1 Canadian LP in global medical cannabis revenues

Leadership in key markets such as Germany, UK, Poland and Australia

Focus on quality and shift to premium brands

Margin accretive acquisition of Thrive and its award-winning premium Greybeard brand

Delivering a continuous stream of innovation to the market

High margin licensing opportunities for IP in genetics and biosynthesis

One of the largest suppliers of propagated vegetables and ornamental plants in North America

Track record of profitable, cash flow positive operations

3

Canadian Medical Market Leadership

# 1

CanadianMedical

Share by Revenue

81%

of Revenue Came From

High Value Insured

Patients in FY22Q4

1. Source: Sanofi Pasteur 2020 Healthcare Survey

Consistent, high gross margin revenue stream

• Direct-to-patientdistribution model; end-to-end experience from

medical consultation to prescription fulfillment

• Focus on insured patient groups with high repeat purchase rate

Opportunities to expand our presence

• Opportunity to capture share from fragmented market in which ~60% are

small players

• Opportunity for increased benefit plan coverage; despite 64% of employees believing cannabis should be covered, only 37% of employers do so (1)

4

Aurora Canadian Medical Platform

Significant investment in technology & fulfillment infrastructure provides competitive barrier to entry & high retention rates in key patient groups

Best-in-class client experience with pipeline of web and eCommerce enhancements:

• Faster loading on mobile & desktop
• Dynamic filtering of products
• Shop again & favourite buttons
• Improved product information cards
• Same day shipping countdown timer
• And much more to come…

A breadth of offerings that cater to multiple patient segments; selection from Aurora brands as well as premium craft cannabis strains sourced from selected small growers

Sustainable high margin revenues in the Canadian medical segment

5